A Pilot Study of APX005M in Combination With Concurrent Chemoradiation as Neoadjuvant Therapy for Resectable Esophageal and Gastroesophageal Junction Cancers

Trial Profile

A Pilot Study of APX005M in Combination With Concurrent Chemoradiation as Neoadjuvant Therapy for Resectable Esophageal and Gastroesophageal Junction Cancers

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 02 Sep 2017

At a glance

  • Drugs APX 005M (Primary) ; Carboplatin; Paclitaxel
  • Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer; Squamous cell cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 28 Aug 2017 Planned initiation date changed from 21 Aug 2017 to 30 Sep 2017.
    • 08 Aug 2017 Planned initiation date changed from 1 Jul 2017 to 21 Aug 2017.
    • 26 May 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top